JP2024533375A5 - - Google Patents

Info

Publication number
JP2024533375A5
JP2024533375A5 JP2024515385A JP2024515385A JP2024533375A5 JP 2024533375 A5 JP2024533375 A5 JP 2024533375A5 JP 2024515385 A JP2024515385 A JP 2024515385A JP 2024515385 A JP2024515385 A JP 2024515385A JP 2024533375 A5 JP2024533375 A5 JP 2024533375A5
Authority
JP
Japan
Prior art keywords
cd3γ
cd3δ
cd3ε
hla
nlrc5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515385A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533375A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/042869 external-priority patent/WO2023039041A1/en
Publication of JP2024533375A publication Critical patent/JP2024533375A/ja
Publication of JP2024533375A5 publication Critical patent/JP2024533375A5/ja
Pending legal-status Critical Current

Links

JP2024515385A 2021-09-10 2022-09-08 同種異系ヒトｔ細胞の代替生成 Pending JP2024533375A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163242909P 2021-09-10 2021-09-10
US63/242,909 2021-09-10
PCT/US2022/042869 WO2023039041A1 (en) 2021-09-10 2022-09-08 Alternative generation of allogeneic human t cells

Publications (2)

Publication Number Publication Date
JP2024533375A JP2024533375A (ja) 2024-09-12
JP2024533375A5 true JP2024533375A5 (enExample) 2025-08-04

Family

ID=85507013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515385A Pending JP2024533375A (ja) 2021-09-10 2022-09-08 同種異系ヒトｔ細胞の代替生成

Country Status (12)

Country Link
US (1) US20230190809A1 (enExample)
EP (1) EP4399280A4 (enExample)
JP (1) JP2024533375A (enExample)
KR (1) KR20240058915A (enExample)
CN (1) CN118355111A (enExample)
AU (1) AU2022343108A1 (enExample)
CA (1) CA3231670A1 (enExample)
CO (1) CO2024004474A2 (enExample)
IL (1) IL311307A (enExample)
MX (1) MX2024002903A (enExample)
TW (1) TW202321436A (enExample)
WO (1) WO2023039041A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024527902A (ja) * 2021-07-26 2024-07-26 カイト ファーマ インコーポレイテッド Ｄｎｖｓｉｇ３及びｄｎｖｓｉｇ８受容体並びにその使用方法
CA3252595A1 (en) 2022-05-25 2023-11-30 Metagenomi Therapeutics, Inc. LIVER ENZYME EXPRESSION SUPPLEMENTATION
WO2024023802A2 (en) * 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
CN118109416B (zh) * 2023-03-30 2024-11-22 广州百吉生物制药有限公司 功能增强型工程化免疫细胞及其制备和应用
WO2025031347A1 (zh) * 2023-08-07 2025-02-13 上海交通大学 肿瘤疫苗及其用途
CN117025541B (zh) * 2023-08-15 2025-10-17 福建医科大学附属协和医院 一种靶向b7-h3并共表达细胞因子和趋化因子的car-t细胞及其用途
CN116987699B (zh) * 2023-09-05 2024-08-27 深圳市艾迪贝克生物医药有限公司 用于制备通用型car-t细胞的基因片段、其工具系统及应用
WO2025097031A1 (en) * 2023-11-02 2025-05-08 Metagenomi, Inc. Compositions and methods for cell therapy
WO2025231191A1 (en) * 2024-05-01 2025-11-06 Cargo Therapeutics, Inc. Compositions and methods for allogeneic immune cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2752933C2 (ru) * 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
EP3294342A4 (en) * 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
BR112019023608A2 (pt) * 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
CA3082204A1 (en) * 2017-12-13 2019-06-20 Janssen Biotech, Inc. Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
CN110616186A (zh) * 2018-06-20 2019-12-27 西安桑尼赛尔生物医药有限公司 增加同种异体t细胞移植相容性的方法及其应用
WO2020103013A1 (en) * 2018-11-21 2020-05-28 Nanjing Bioheng Biotech Co., Ltd Modified t cells and uses thereof
US11739136B2 (en) * 2019-03-18 2023-08-29 Innovative Cellular Therapeutics Holdings, Ltd. Inducible dominant negative PD-1 and uses in adoptive cell therapy
CN114729059A (zh) * 2019-09-11 2022-07-08 宾夕法尼亚大学董事会 包含前列腺干细胞抗原(psca)嵌合抗原受体(cars)的组合物和方法
WO2022256448A2 (en) * 2021-06-01 2022-12-08 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes

Similar Documents

Publication Publication Date Title
US20260055157A1 (en) Methods of making chimeric antigen receptor-expressing cells
ES2995785T3 (en) Gene therapy
KR102357004B1 (ko) 입양 세포 면역요법의 효능을 강화하기 위한 조성물 및 방법
JP2022531911A (ja) Ｂｃｍａを標的とする操作された免疫細胞及びその使用
EP4112721A1 (en) Engineered immune cell expressing nk inhibitory molecule and use thereof
JP2023534928A (ja) 改変免疫細胞及びその使用
EP4194472A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
KR20200103708A (ko) 인간 메소텔린을 특이적으로 인식하는 세포 표면 분자, il-7, 및 ccl19 를 발현하는 면역 담당 세포
CA3207627A1 (en) Dendritic cell activating chimeric antigen receptors and uses thereof
CN117441010A (zh) 从诱导多能干细胞产生α-βT细胞的组合物和方法
JP7862857B2 (ja) キメラ抗原受容体発現免疫担当細胞
CN112204135B (zh) 一种表达cd3抗体受体复合物的免疫细胞及其用途
JP2025535365A (ja) Ｉｌ１８と結合した新規ｃｄ１９結合体を含むｃａｒ－ｔ構築物およびその使用方法
CN119907857A (zh) 包含嵌合衔接子多肽的组合物和方法
Yu et al. CAR NK cell therapy for solid tumors: potential and challenges
CN115785279A (zh) 包含新型共刺激结构域的嵌合抗原受体及其用途
CN115873801A (zh) 工程化免疫细胞及其用途
JP2024502170A5 (enExample)
JP2024502170A (ja) 癌のための改良された養子細胞移植療法
CN115786268A (zh) 工程化免疫细胞及其用途
CA3171344C (en) Engineered immune cell expressing nk inhibitory molecule and use thereof
US20230303643A1 (en) Constitutively active tcf1 to promote memory-associated traits in car t cells
HK40110123A (en) Engineered immune cell targeting bcma and use thereof
KR20260011159A (ko) Nk 세포의 증폭 수단 및 방법
WO2025130895A1 (zh) 一种免疫细胞的制备方法及其用途